Llwytho...

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential

Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Onco Targets Ther
Prif Awduron: Baldini, Capucine, Champiat, Stéphane, Vuagnat, Perrine, Massard, Christophe
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove Medical Press 2019
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6452813/
https://ncbi.nlm.nih.gov/pubmed/31040693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S141040
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!